Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7371379 Dosages for treatment with anti-ErbB2 antibodies

Patent 7371379 was granted and assigned to Genentech on May, 2008 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Sharon A. Baughman0

Steven Shak0

Date of Patent

May 13, 2008

0

Patent Application Number

106001520

Date Filed

June 20, 2003

0

Patent Citations Received

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

0

US Patent 12024569 HER2/neu-specific antibodies and methods of using same

0

Patent Primary Examiner

Alana M. Harris

0

Patent abstract

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7371379 Dosages for treatment with anti-ErbB2 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.